These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27684806)

  • 1. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.
    Qin Z; Li X; Zhang J; Tang J; Han P; Xu Z; Yu Y; Yang C; Wang C; Xu T; Xu Z; Zou Q
    Medicine (Baltimore); 2016 Sep; 95(39):e4801. PubMed ID: 27684806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
    Zhang C; Jing T; Wang F; Gao X; Xu C; Sun Y
    Actas Urol Esp; 2014 Apr; 38(3):184-91. PubMed ID: 24507454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.
    Qi WX; Shen Z; Yao Y
    J Cancer Res Clin Oncol; 2011 Dec; 137(12):1785-90. PubMed ID: 21915752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
    Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
    Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
    Song P; Huang C; Wang Y
    Int J Surg; 2018 Aug; 56():133-140. PubMed ID: 29906643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
    Wong YN; Manola J; Hudes GR; Roth BJ; Moul JW; Barsevick AM; Scher RM; Volk MJ; Vaughn DJ; Williams SD; Fisch MJ; Cella D; Carducci MA; Wilding G
    Clin Genitourin Cancer; 2018 Apr; 16(2):e315-e322. PubMed ID: 29173976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer.
    Kuramoto T; Inagaki T; Fujii R; Sasaki Y; Nishizawa S; Nanpo Y; Matusmura N; Kohjimoto Y; Hara I
    Int J Clin Oncol; 2013 Oct; 18(5):890-7. PubMed ID: 22936562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer.
    Laber DA; Chen MB; Jaglal M; Patel A; Visweshwar N
    Clin Genitourin Cancer; 2018 Dec; 16(6):473-481. PubMed ID: 30072309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer.
    Hatano K; Nishimura K; Nakai Y; Yoshida T; Sato M; Kawashima A; Mukai M; Nagahara A; Uemura M; Oka D; Nakayama M; Takayama H; Shimizu K; Meguro N; Tanigawa T; Yamaguchi S; Tsujimura A; Nonomura N
    Int J Clin Oncol; 2013 Aug; 18(4):704-10. PubMed ID: 22688162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
    Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
    Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
    Du J; Yang Q; Chen XS; Tian J; Yao X
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.
    Nakai Y; Nishimura K; Nakayama M; Uemura M; Takayama H; Nonomura N; Tsujimura A;
    Int J Clin Oncol; 2014 Feb; 19(1):165-72. PubMed ID: 23456140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis.
    Wu Y; Shao N; Shen ZX; Li Q; Wang Y; Li C; Ma G; Dong J; Lu XJ; Feng NH
    Eur Rev Med Pharmacol Sci; 2014; 18(21):3291-6. PubMed ID: 25487941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Bianco V; Ponchietti R; Barbanti G; Francini E
    Clin Genitourin Cancer; 2015 Oct; 13(5):441-6. PubMed ID: 25920994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Low-Dose Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients].
    Fukui T; Nakamura K; Sakatani T; Atsuta T; Kato T; Fukumoto T; Ito M; Inoue K; Terai A
    Hinyokika Kiyo; 2017 Feb; 63(2):57-62. PubMed ID: 28264534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
    Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
    Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.